13 results about "Synthetic nucleotide" patented technology

The present disclosure provides a complex for synthesizing one or more nucleotide strands of interest and a method for synthesizing one or more nucleotide strands of interest. The complex for synthesizing one or more nucleotide strands of interest includes nucleotide fragments and a double-stranded oligonucleotide ligase, wherein the nucleotide fragments are hybridized to form a double-stranded oligonucleotide; the double-stranded oligonucleotide ligase is a ligase capable of sealing nicks in the double-stranded oligonucleotide; and at least one strand of the double-stranded oligonucleotide is a nucleotide strand of interest; and the nucleotide fragments include a first fragment and a second fragment, the first fragment contains a 5′-phosphate group, and the first fragment is synthesized in a 3′- to 5′-direction; and the second fragment contains a 3′-hydroxyl group, and the second fragment is synthesized in a 5′- to 3′-direction.

A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.

The invention belongs to the technical field of biology. The invention provides a recombinant protein, an amino acid sequence of the recombinant protein is formed by repeatedly connecting dominant epitopes of canine parvovirus VP2 protein in series, the amino acid sequence of the canine parvovirus recombinant protein is converted into a corresponding nucleotide sequence by adopting escherichia coli preferred codons, the nucleotide sequence is chemically synthesized, and a recombinant expression vector is constructed; therefore, the expression quantity of the recombinant protein in escherichia coli is improved. The invention also relates to a method for establishing a bacteriophage library by immunizing a mouse with the recombinant protein, obtaining a corresponding canine parvovirus VP2 protein single-chain antibody scfv sequence through panning screening, constructing a complete mouse IgG1 antibody sequence expression vector from the obtained scfv sequence, expressing a monoclonal antibody through transient HEK293F cells, and purifying the monoclonal antibody, thereby obtaining the canine parvovirus VP2 protein single-chain antibody. An optimal monoclonal antibody pairing combination is determined through an immunofluorescence orthogonal experiment.

The application discloses a nerve necrosis virus goliath grouper oral vaccine and a preparation method thereof. The amino acid sequence of the antigen of the nerve necrosis virus goliath grouper oral vaccine is shown as SEQ ID No: 1. The preparation method comprises the following steps: 1) construction of a recombinant plasmid: a fusion gene with a nucleotide sequence shown as SEQ ID No: 1 is synthesized, the fusion gene is inserted into an expression vector to obtain a recombinant vector, the recombinant vector is transformed into a prokaryotic expression bacterium, and the prokaryotic expression bacterium is cultured to select a successfully transformed prokaryotic expression bacterium; 2) the successfully transformed prokaryotic expression bacterium is induced to express; and 3) the induced prokaryotic expression bacterium is used to feed halocyprid larvae, and halocyprid larvae enriched and wrapped with the prokaryotic expression bacterium are obtained to obtain a nerve necrosis virus infection goliath grouper medicine. The nerve necrosis virus goliath grouper oral vaccine has high protection rate and an immune protection efficiency of 100% for goliath groupers. The application can be applied to the prevention and control of nerve necrosis virus diseases in the goliath grouper breeding process.

The present disclosure discloses a method for synthesizing nucleotide strands, relating to the biology field. The synthesizing method includes regulating a temperature for synthesizing the nucleotide strands to ≥42° C. or performing a procedure of high-temperature denaturation-low-temperature annealing for at least one time during the synthesis, thus achieving efficient ligation of natural nucleic acid fragments and / non-natural nucleic acid fragments. This method can effectively reduce byproducts produced during the synthesis of nucleotide strands, improve the efficiency of synthesis of nucleotide strands of interest, and facilitate large-scale production of high-quality nucleotide strands.

A composition for synthesizing a nucleotide chain and a synthesis method for a nucleotide chain, which belong to the technical field of nucleotides. The composition for synthesizing a nucleotide chain comprises a nucleotide fragment and a double-stranded ligase. The nucleotide fragment is used for forming a double-stranded structure; the double-stranded ligase is a ligase capable of sealing a nick in the double-stranded structure; and at least one strand of the double-stranded structure is a target nucleotide chain. The nucleotide fragment comprises a first fragment and a second fragment; the 5' end of the first fragment contains a monophosphate group, and the first fragment is synthesized in the 3' to 5' direction; and the 3' end of the second fragment contains a hydroxyl group, and the second fragment is synthesized in the 5' to 3' direction.

This invention belongs to the field of biotechnology. It provides a recombinant protein whose amino acid sequence consists of two dominant epitopes of cardiac troponin I (cTnI) repeated in tandem. The amino acid sequence is converted into a corresponding nucleotide sequence using E. coli-preferred codons. The nucleotide sequence is then chemically synthesized and a recombinant expression vector is constructed, thereby increasing the expression level of the recombinant protein in E. coli. This invention also involves using this recombinant protein to immunize mice to establish a phage library, obtaining the corresponding cardiac troponin I single-chain antibody scfv sequence through panning and screening, constructing a complete mouse IgG1 antibody sequence expression vector from the obtained scfv sequence, expressing the monoclonal antibody via transient transfection of HEK293F cells, purifying the monoclonal antibody, and determining the optimal monoclonal antibody pairing using an immunofluorescence orthogonal experiment.

The present disclosure provides optionally modified small interfering ribonucleic acid (siRNA) compounds, pharmaceutical compositions, and methods of use thereof. The optionally modified siRNA compounds may be tailored to improve delivery to the central nervous system, to reduce off-target effects, and / or to reduce expression of mRNA transcribed from a gene of interest (e.g., LRRK2, VEGFA, or ANGPT2), i.e., to translate to a protein. In some embodiments, the sense strand of the siRNA comprises a synthetic nucleotide and / or a lipid conjugated to one or both ends of the sense strand, or within any position of the sense strand.

This disclosure provides a nucleotide dimer, its preparation method, and its uses, belonging to the field of nucleic acid drug technology. The nucleotide dimer can be synthesized as a whole into a nucleotide chain. Compared to synthesizing nucleotides one by one through two steps, the synthesis method using the nucleotide dimer provided in this disclosure involves fewer steps, higher synthesis efficiency, less impurities, and higher product purity, showing promising application prospects.

A biological system for generating and preserving a repository of personalized, humanized transplantable cells, tissues, and organs for transplantation, wherein the biological system is biologically active and metabolically active, the biological system having genetically reprogrammed cells, tissues, and organs in a non-human animal for transplantation into a human recipient, wherein the non-human animal does not present one or more surface glycan epitopes and specific sequences from the wild-type swine's SLA is replaced with a synthetic nucleotides based on a human captured reference sequence from a human recipient's HLA.

A composition for the synthesis of a nucleotide chain and a method for the synthesis of a nucleotide chain, belonging to the art of nucleotides. The composition for the synthesis of a nucleotide chain comprises a nucleotide fragment and a double-stranded ligase, wherein the nucleotide fragment is for forming a double-stranded structure, the double-stranded ligase is a ligase capable of closing gaps in the double-stranded structure, and at least one of the strands of the double-stranded structure is a target nucleotide chain, the nucleotide fragment comprises a first fragment and a second fragment, the first fragment contains a monophosphate group at its 5' end and the first fragment is synthesized in the direction from 3' to 5', the second fragment contains a hydroxyl group at its 3' end and the second fragment is synthesized in the direction from 5' to 3'.

This disclosure provides optionally modified small interfering ribonucleic acid (siRNA) compounds, pharmaceutical compositions, and methods of use of same. The optionally modified siRNA compounds may be tailored for improved delivery to the central nervous system, reduced off-target effects, and / or reducing the expression, i.e., translation into protein, of mRNA transcribed from a gene of interest, e.g. LRRK2, VEGFA, or ANGPT2. In some embodiments, the sense strand of the siRNA comprises a synthetic nucleotide and / or a lipid conjugated to one or both ends or within any positions of the sense strand.

The present invention provides for compositions and methods for deploying ddhNTPs as immunomodulatory therapeutics to modulate P2 receptors, as nucleotidase inhibitors, for applications like host-acting anti-infectives, oncolytics, anti-aging agents, or tissue regeneration agents.